Tarceva erlotinib: Completed Phase III enrollment

Last quarter, Genentech completed enrollment of 636 patients with non-squamous NSCLC in the Phase III BETA Lung trial evaluating 150 mg/day Tarceva plus either Avastin bevacizumab or placebo as secon...